Curis to Present at Upcoming Healthcare Conferences in September
Curis, a biotechnology company focused on cancer therapeutics, announced the participation of CEO James Dentzer in two upcoming virtual healthcare conferences. The Morgan Stanley Virtual Global Healthcare Conference is set for September 10, 2021, at 11:00 a.m. ET, followed by the Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20 a.m. ET. Presentations will be available via live webcast and later as a replay on Curis' investor website. Curis is developing key cancer drugs, including CA-4948, which is in clinical trials for non-Hodgkin's lymphoma and acute myeloid leukemia.
- None.
- None.
LEXINGTON, Mass., Sept. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the following upcoming conferences:
- Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10, 2021 at 11:00 a.m. ET
- Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 9:20 a.m. ET.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for approximately 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-301368126.html
SOURCE Curis, Inc.
FAQ
When will Curis present at the Morgan Stanley Virtual Global Healthcare Conference?
What is CA-4948 and its significance for Curis?
Where can I watch the live webcast of Curis' conference presentations?
What other conferences will Curis participate in September 2021?
What collaborations is Curis involved in for cancer treatment?
